Search results for "Migraine"
ACP guideline offers advice, evidence on treating acute episodic migraines
The new guideline recommends adding a triptan if nonpregnant adult patients with moderate to severe episodic migraines do not have a response to NSAID or acetaminophen therapy.
https://immattersacp.org/weekly/archives/2025/03/18/1.htm
18 Mar 2025
New ACP guideline on migraine prevention advises starting with monotherapy
ACP's recommendations to prevent migraines in nonpregnant adults favor metoprolol or propranolol, valproate, venlafaxine, or amitriptyline as initial therapy and reported that all treatments provide similar net clinical benefit.
https://immattersacp.org/weekly/archives/2025/02/04/1.htm
4 Feb 2025
Oral drugs for acute migraines compared head to head
A meta-analysis found that triptans are the most effective medication class for migraine; of individual drugs, eletriptan and ibuprofen provide the most sustained pain relief and are more efficacious than the recently approved drugs lasmiditan, rimegepant, and ubrogepant.
https://immattersacp.org/weekly/archives/2024/09/24/1.htm
24 Sep 2024
Prophylactic injectable monoclonal antibody reduced migraine days, industry trial finds
Compared with nonspecific oral drugs, patients treated with erenumab were six times more likely to achieve 50% or more reduction in monthly migraine days and were 11 times more likely to complete the treatment on the first attempt, authors reported.
https://immattersacp.org/weekly/archives/2024/04/02/4.htm
2 Apr 2024
Ubrogepant appears effective for early acute treatment of migraine
An industry-funded trial found that ubrogepant was associated with absence of moderate or severe headache within 24 hours 46% of the time versus 29% with placebo when taken during the prodrome period (nonaura symptoms preceding headache onset).
https://immattersacp.org/weekly/archives/2023/11/21/2.htm
21 Nov 2023
Migraine studies find new drug, several existing options all effective for acute treatment
An industry-funded trial found that migraine pain resolved sooner with eptinezumab than placebo, while a meta-analysis found that several established and newer therapies for the acute treatment of migraine were associated with reductions in short-term pain.
https://immattersacp.org/weekly/archives/2021/06/22/5.htm
22 Jun 2021
Similar improvements in migraine frequency seen with mindfulness meditation vs. headache education
While mindfulness-based stress reduction did not improve migraine frequency more than headache education in a small randomized trial, it significantly improved disability, quality of life, self-efficacy, pain catastrophizing, and depression out to 36 weeks.
https://immattersacp.org/weekly/archives/2020/12/22/6.htm
22 Dec 2020
Erenumab reduced migraines in patients who didn't respond to other treatments, industry-funded study found
An industry-funded study found improvements in primary and secondary endpoints related to migraines with the drug compared to placebo, with similar safety and tolerability.
https://immattersacp.org/weekly/archives/2018/10/30/4.htm
30 Oct 2018
Migraine associated with cardiovascular risks
Higher absolute risks of cardiovascular disease were observed among patients with migraine across most outcomes and follow-up periods during 19 years of follow-up.
https://immattersacp.org/weekly/archives/2018/02/06/4.htm
6 Feb 2018
Migraineurs may have more risk of hemorrhagic stroke
People with migraine may have an increased risk of hemorrhagic stroke, especially women younger than 45, a meta-analysis found.
https://immattersacp.org/weekly/archives/2013/10/08/5.htm
8 Oct 2013